This month’s Research Digest (#127) highlights Australian-led research advancing our understanding of ME/CFS across quality of life and biology. A longitudinal study shows a persistent and substantial illness burden, with little change in symptoms or functioning over time and ongoing challenges accessing support. Complementary multi-omics and genetic studies point to disruptions in energy metabolism, immune function, lipid processing, and vascular systems. Together, these findings reinforce that ME/CFS is a complex, multi-system condition requiring integrated research and coordinated policy and clinical responses.
Contributing Digesters: Anna & Simone.
Please note: The Research Digest shares current scientific findings for awareness and discussion. It is not a substitute for medical advice or treatment guidance, as much of the research featured is in its early stages and requires further confirmation.
You can join our community by signing up here to our mailing list and receiving the Digest straight to your inbox at the end of every month. We appreciate the support of everyone who reads the Digest – we encourage regular subscribers to support us with a monthly suggested donation of $2.
QUALITY OF LIFE
Sustained illness burden over time among Australians with myalgic encephalomyelitis/ chronic fatigue syndrome
Authors: Weigel B, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S (Griffith University, Australia)
Publication: PLOS One (December, 2025)
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12747376/pdf/pone.0338433.pdf
Easy Read Overview: Many people with ME/CFS cannot work and need support, but they often miss out on government help because the illness is not recognised as a disability in Australia. This study followed 32 adults with ME/CFS over 12 months to see how their symptoms and daily lives changed. Participants reported a high number of ongoing symptoms, with little to no improvement over time. The study found that quality of life stayed very low and most people could not work much, showing a need for policy changes to improve access to support.
Although many people with ME/CFS are unable to work and require support, they are often deemed ineligible for essential government-funded support because ME/CFS is not recognised as a disability in Australia. This longitudinal study investigated persistence of symptoms to provide evidence to inform Australian policy reform.
The study included 32 participants with ME/CFS, aged 18 to 65 years, who met the Canadian Consensus diagnostic Criteria or International Consensus Criteria. Participants’ symptoms and outcomes were monitored over a 12-month period, with data collected at six-month intervals. Participants provided self-reported sociodemographic information, medical history, illness presentation, as well as outcomes, including quality-of-life (QoL), functional capacity and fatigue impact. QoL data were compared with Australian population data.
At each time point, a median of 30 to 34 symptoms was reported, with at least 25% of participants reporting more than 40 symptoms. Post-exertional malaise (PEM) was reported by all participants. The symptoms with the greatest burden were PEM, cognitive overload, impaired capacity for reading and comprehension, unrefreshed sleep, general malaise, and widespread pain.
Almost all participants reported impacts on life activities throughout the study with no statistically significant changes over the 12-months. Participation in work, social and recreational activities was restricted in all participants. Most (n=19/32, 59%) were unemployed due to ME/CFS. Over half of unemployed participants were not receiving the Disability Support Pension. Of those employed, none were working full-time. The mean time spent in paid work was 12.7 to 14.2 hours/week. Over half of participants (n=14/32, 56%) were receiving informal support.
Compared with the general population, QoL was significantly reduced among pwME/CFS. No statistically significant changes in symptoms, severity or outcomes were found over the 12 month period, suggesting a persistence to the condition.
The authors conclude that people living with ME/CFS face substantial, sustained illness impairments, highlighting the need for policy reform to improve access to disability and support services in Australia.
BIOLOGY
Multi-omics identifies lipid accumulation in myalgic encephalomyelitis/chronic fatigue syndrome cell lines: a case-control study
Author: Missailidis D, Armstrong CW, Anderson D, Allan CY, Sanislav O, Smith PK, … Fisher, PR (La Trobe University)
Publication: Journal of Translational Medicine (January, 2026)
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12874856/
Easy Read Overview: Metabolic problems may play a role in ME/CFS, including how the body uses fats and supports the immune system. This study looked at cells from 15 women with ME/CFS and 17 healthy controls to compare metabolic and lipid changes. While no single metabolite was different, several key pathways were disrupted, and one lipid (PC(O-38:4)) was lower in ME/CFS, with an overall build-up of lipids. These findings suggest problems with how cells process fats, which may affect energy
Metabolic disruption has been proposed as a key feature in ME/CFS, and recent studies have suggested that problems with immune function and lipid metabolism may be related. This study used a multi-omics approach to study metabolic and lipid changes in ME/CFS.
The study included female participants: 15 with ME/CFS (Canadian Consensus Criteria) and 17 healthy controls (HC). Researchers used existing lymphoblastoid cell lines derived from participants and analysed polar metabolome and nonpolar lipodome using metabolomics, lipidomics, and gene expression data.
Metabolomic analysis found no significant differences in individual metabolites between the groups. However, pathway analysis showed disruption in several metabolic pathways, including B6 and thiamine metabolism, and steroid hormone biosynthesis. One lipid species, PC(O-38:4), was significantly reduced in ME/CFS and was able to differentiate ME/CFS from HC in most cases. The ME/CFS group showed an overall accumulation of lipids compared to HC, suggesting altered lipid processing or breakdown.
The authors suggest that changes in lipid metabolism may be involved in ME/CFS and could contribute to impaired energy production. The study highlights lipid processing as a potential area for future research, including whether it could lead to new biomarkers or treatment targets.
BIOLOGY
Mapping the complexity of ME/CFS: Evidence for abnormal energy metabolism, altered immune profile, and vascular dysfunction
Authors: Heng B, Gunasegaran B, Krishnamurthy S, Bustamante S, Pires AS, Chow S, … Guillemin GJ (Macquarie University, Australia)
Publication: Cell Reports Medicine (December, 2025)
Link: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00587-7
Easy Read Overview: ME/CFS may involve problems with how the body makes energy, the immune system, and blood vessels. This study looked at blood samples from 61 people with ME/CFS and 61 matched healthy controls. It found signs of lower energy production in immune cells, changes in immune cell types, and higher levels of proteins linked to blood vessels and inflammation. These findings suggest that several body systems are affected, and that studying them together may help better understand the condition.
Increasing evidence suggests that ME/CFS involves disruption to energy metabolism, immune and endothelial function. This study used a multi-omics approach to examine how these systems may be linked in ME/CFS.
The study included 61 people with ME/CFS (Canadian Consensus Criteria) and 61 age- and sex-matched healthy controls (HC). Researchers analysed blood samples using metabolomics, immune cell profiling, and plasma proteomics to assess energy metabolism, immune cell populations, and proteins related to vascular function.
The study found evidence of disrupted energy metabolism in immune cells, including higher levels of AMP and ADP and a reduced ATP/ADP ratio, suggesting lower energy production. Differences were also seen in immune cell populations, with reduced proportions of some T cells, natural killer (NK) cells, and dendritic cells. In addition, several plasma proteins linked to blood vessel function and inflammation were increased in the ME/CFS group.
The authors suggest that these combined changes across energy, immune, and vascular systems may contribute to ME/CFS. The authors also suggest that taking a multi-modal approach is necessary in the study of ME/CFS due to the complexity and heterogeneity involved.
BIOLOGY
Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK biobank
Authors: Huang K, Muneeb M, Thomas N, Schneider-Futschik EK, Gooley PR, Ascher DB, Armstrong CW (University of Melbourne, Australia)
Publication: iScience (January, 2026)
Link: https://www.sciencedirect.com/science/article/pii/S2589004225025775
Easy Read Overview:ME/CFS may involve changes in how the body uses energy, and genetics may play a role. This study looked at genetic and metabolite data from 875 people with ME/CFS and over 36,000 healthy controls. It found that many small genetic changes across different body systems, including the immune system and metabolism, may work together to disrupt energy use and other body processes in ME/CFS. However, the study cannot show cause and effect, and more research is needed to confirm these findings.
Metabolomic and transcriptomics studies have identified changes in energy metabolism in ME/CFS. While twin and family studies have suggested a heritable component to the condition, until recently identification of clear genetic factors has remained elusive. This study explored the role of genetic factors in the metabolic disruption found in ME/CFS.
The study included genetic and metabolite data from 875 people with ME/CFS and 36,033 healthy controls from the UK Biobank. Researchers used a metabolite-linked genome-wide association study (mGWAS) and integrated this with additional genetic analyses to identify biological pathways linked to ME/CFS.
The study found that genetic signals were spread across multiple biological systems rather than a single pathway. These included genes involved in immune regulation, lipid metabolism, endoplasmic reticulum (ER) stress, and extracellular matrix and vascular function. The findings suggest that genetic risk in ME/CFS may affect how different systems work together, particularly those involved in energy use, cell stress, and recovery.
The authors note several limitations. The ME/CFS sample was relatively small for a genome-wide association study, and the UK Biobank tends to include healthier-than-average participants, which may affect the results. Also, as this is an associational study, it cannot show cause and effect. The authors recommend future work include Mendelian randomisation to strengthen causal inference.
The authors suggest that ME/CFS may involve polygenic risk, where many small genetic changes combine to affect multiple systems. This may help explain the complexity and variation seen in ME/CFS.
The study highlights the need for approaches that look at multiple biological systems together, rather than focusing on a single cause.
